Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
2.03Enterprise Value over EBITDA
VS
Market
Sector
Industry
History
$ 12.4Close
$ 6.3 - $ 178.5 52-Week Range
Ticker Information
Ticker
BCTXCompany Name
BRIACELL THERAPEUTICS CORPSector
HealthcareIndustry
BiotechnologyExchange
NASDAQBRIACELL THERAPEUTICS CORP - Enterprise Value over EBITDA Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
BCTX - EV/EBITDA Historical data
| Date | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | Enterprise Value | Enterprise Value over EBITDA |
|---|---|---|---|
| 3/31/2025 | $ 4.41M | $ 8.95M | 2.03 |
| 12/31/2024 | $ 1.26M | $ 8.53M | 6.77 |
| 9/30/2024 | $ -2.21M | $ 21.09M | 0 |
| 6/30/2024 | $ -4.85M | $ 29.25M | 0 |
| 3/31/2024 | $ -20.78M | $ 25.03M | 0 |
| 12/31/2023 | $ -17.21M | $ 40.1M | 0 |
| 9/30/2023 | $ -11.85M | $ 53.48M | 0 |
| 6/30/2023 | $ -23.26M | $ 56.42M | 0 |
| 3/31/2023 | $ -18M | $ 66.6M | 0 |
| 12/31/2022 | $ -16.05M | $ 77.76M | 0 |
Key Performance Insights, Last 5 Years
- BRIACELL THERAPEUTICS CORP's latest trailing twelve months (TTM) EV/EBITDA stands at 0.
- Over the past 5 years, BRIACELL THERAPEUTICS CORP's average EV/EBITDA has been 4.4.
- The median EV/EBITDA for BRIACELL THERAPEUTICS CORP during this period was 4.4
- BRIACELL THERAPEUTICS CORP reached its highest EV/EBITDA over the past 5 years at 6.77.
- The lowest EV/EBITDA recorded by BRIACELL THERAPEUTICS CORP in the same timeframe 2.03
Similar metrics to EV/EBITDA:
- Enterprise Value over EBIT - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest and taxes [EBIT].
- Enterprise Value - [Calculation] Enterprise value (EV) refers to the total value of a business and is frequently used as a more elaborate substitute for market capitalization. EV is calculated as a company's [MarketCap] plus its [Debt] minus cash and cash equivalents [CashnEq].
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
- Enterprise Value over Free Cash Flow - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its Free Cash Flow [FCF].
Definition of Enterprise Value over EBITDA
[Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].EV / EBITDA
(=) EV/EBITDA EV/EBITDA for BRIACELL THERAPEUTICS CORP is calculated as follows: EV [ $ 0 ] / EBITDA [ $ -3.76M ]
(=) EV/EBITDA [ 0 ] BCTX - Enterprise Value over EBITDA, Last 5 years
2.03
Minimum
Mar 31, 2025
6.77
Maximum
Dec 31, 2024
4.4
Average
4.4
Median
EV/EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EV/EBITDA for companies in the Total Stock Market. The average EV/EBITDA of the companies is 13.48 with a standard deviation of 7.65.
The following table provides additional summary stats:
EV/EBITDA in the Market:
| filtered constituents | 2.44K |
|---|---|
| min | 0.01 |
| max | 40.82 |
| average | 13.48 |
| median | 11.75 |
| std | 7.65 |